Chlorohydrin-arglabinAlternative Names: Arglabin chlorohydrin
Latest Information Update: 02 Sep 2002
At a glance
- Originator NuOncology Labs; Paracure
- Mechanism of Action Squalene synthase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 06 Sep 1999 New profile
- 06 Sep 1999 Preclinical development for Cancer in USA (Unknown route)